✦ LIBER ✦

Genetic variants ofCYP3A5,CYP2D6,SULT1A1,UGT2B15and tamoxifen response in postmenopausal patients with breast cancer

✍ Scribed by Pia Wegman, Sauli Elingarami, John Carstensen, Olle Stål…

Book ID: 120700299
Publisher: BioMed Central
Year: 2007
Tongue: English
Weight: 438 KB
Volume: 9
Category: Article
ISSN: 1465-5411
DOI: 10.1186/bcr1640

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CYP2D6 genotype affects outcome in postm

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy

✍ AM Thompson, S Bray, AM Johnson, P Quinlan, DM Nikloff, DG Evans… 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 390 KB

Association between Genetic Polymorphism

Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment

✍ Park, Hyung Seok; Choi, Ji-Yeob; Lee, Mi-Jeong; Park, Seho; Yeo, Chang-Woo; Lee, 📂 Article 📅 2011 🏛 Korean Academy of Medical Sciences 🌐 English ⚖ 573 KB

CYP2D6 Genotype and Tamoxifen Response i

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

✍ Regan, M. M.; Leyland-Jones, B.; Bouzyk, M.; Pagani, O.; Tang, W.; Kammler, R.; 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 529 KB

CYP2D6 gene variants: association with b

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

✍ Jean E Abraham, Mel J Maranian, Kristy E Driver, Radka Platte… 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 505 KB

Prevalent breast cancer patients with a

Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users

✍ A. S. Dieudonné; D. Lambrechts; B. Claes; T. Vandorpe; H. Wildiers; D. Timmerman 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 224 KB

Genetic polymorphisms of CYP2D6*10 and C

Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Matthew Goetz; Vera Suman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 1 views

The study by Okishiro et al 1 concludes that the cytochrome P450 (CYP) genotype CYP2D6\*10/\*10 is unlikely to have a clinically significant impact on prognosis in women with breast cancer who receive adjuvant tamoxifen. However, several aspects of the study by Okishiro et al call their conclusions